FindTrial
Sign In

A Phase 3, Open Label, Randomized, Parallel, 26-Week Treatment Study Comparing LY2605541 with Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Asian Insulin Naive Patients with Type 2 Diabetes Mellitus

A Phase 3, Open Label, Randomized, Parallel, 26-Week Treatment Study Comparing LY2605541 with Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Asian Insulin Naive Patients with Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222150
Enrollment
200
Registered
2013-07-18
Start date
2013-07-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus patients

Interventions

investigational material(s) Generic name etc : LY2605541 INN of investigational material : insulin peglispro Therapeutic category code : 249 Other hormone preparations (including antihormone preparati

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Type 2 DM patients at least 20 years of age.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026